Genflow Biosciences plc
LSE: GENF.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eric Jean Leire
- Employees
- 5
- Headquarters
- London, United Kingdom
- IPO year
- 2022
- Market cap
- £12.9M
- Website
- https://genflowbio.com
Loading GENF…
Loading profile data…Frequently asked questions about GENF
What does Genflow Biosciences plc (GENF.L) do?
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral ve...
Where does GENF.L trade?
Genflow Biosciences plc (GENF.L) trades on the London Stock Exchange.
What sector is GENF.L in?
Genflow Biosciences plc (GENF.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Genflow Biosciences plc?
Eric Jean Leire is the chief executive officer of Genflow Biosciences plc (GENF.L).
Where is Genflow Biosciences plc headquartered?
Genflow Biosciences plc is headquartered in United Kingdom.
Does GENF.L pay a dividend?
Genflow Biosciences plc (GENF.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GENF.L go public?
Genflow Biosciences plc (GENF.L) completed its initial public offering in 2022.